Sign in or create an account to add this stock to your watchlist.
About Adamas Pharmaceuticals (NASDAQ:ADMS)
Adamas Pharmaceuticals, Inc. discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease. The company's product candidates under development includes ADS-5102, which is in Phase III clinical trials for the treatment of multiple sclerosis walking impairment; and in Phase II clinical trials for additional indications, such as the treatment of wearing OFF and delaying motor complications in Parkinson's disease, tardive dyskinesia, Huntington's chorea, and Tourette syndrome, as well as non-motor disorders consisting of depression, and anti-psychotic induced weight gain. Its products under development also includes ADS-4101, a modified-release lacosamide that has completed Phase I clinical study for the treatment of partial onset seizures in patients with epilepsy. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADMS
CUSIPN/A
Phone510-450-3500
Debt
Debt-to-Equity Ratio0.63
Current Ratio9.85
Quick Ratio9.73
Price-To-Earnings
Trailing P/E Ratio-7.39
Forward P/E Ratio-5.15
P/E GrowthN/A
Sales & Book Value
Annual Sales$570,000.00
Price / Sales1,388.29
Cash FlowN/A
Price / CashN/A
Book Value$6.29 per share
Price / Book4.66
Profitability
EPS (Most Recent Fiscal Year)($3.97)
Net Income$-89,490,000.00
Net Margins-3,470.97%
Return on Equity-101.94%
Return on Assets-56.21%
Miscellaneous
Employees147
Outstanding Shares26,980,000
Adamas Pharmaceuticals (NASDAQ:ADMS) Frequently Asked Questions
What is Adamas Pharmaceuticals' stock symbol?
Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."
How were Adamas Pharmaceuticals' earnings last quarter?
Adamas Pharmaceuticals (NASDAQ:ADMS) released its quarterly earnings results on Thursday, May, 3rd. The specialty pharmaceutical company reported ($1.35) EPS for the quarter, topping analysts' consensus estimates of ($1.37) by $0.02. The specialty pharmaceutical company had revenue of $2.55 million for the quarter, compared to analyst estimates of $1.71 million. Adamas Pharmaceuticals had a negative net margin of 3,470.97% and a negative return on equity of 101.94%. View Adamas Pharmaceuticals' Earnings History.
What price target have analysts set for ADMS?
11 brokers have issued twelve-month target prices for Adamas Pharmaceuticals' shares. Their predictions range from $31.00 to $55.00. On average, they anticipate Adamas Pharmaceuticals' share price to reach $43.00 in the next year. View Analyst Ratings for Adamas Pharmaceuticals.
What are Wall Street analysts saying about Adamas Pharmaceuticals stock?
Here are some recent quotes from research analysts about Adamas Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company's portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. " (5/9/2018)
- 2. Mizuho analysts commented, "We believe Adamas is building a solid case for the importance of Gocovri within the Parkinson’s treatment paradigm, thereby increasing the company’s attractiveness as a takeout candidate longer-term. We reiterate our Buy rating and $49 PT." (4/20/2018)
Who are some of Adamas Pharmaceuticals' key competitors?
Some companies that are related to Adamas Pharmaceuticals include Amicus Therapeutics (FOLD), Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), Portola Pharmaceuticals (PTLA), Ironwood Pharmaceuticals (IRWD), Clovis Oncology (CLVS), Tesaro (TSRO), Emergent BioSolutions (EBS), Horizon Pharma (HZNP), Global Blood Therapeutics (GBT), The Medicines (MDCO), Arena Pharmaceuticals (ARNA), Heron Therapeutics (HRTX), Evotec A.G. (EVTCY) and ACADIA Pharmaceuticals (ACAD).
Who are Adamas Pharmaceuticals' key executives?
Adamas Pharmaceuticals' management team includes the folowing people:
- Dr. Gregory T. Went Ph.D., Co-Founder, Chairman & CEO (Age 54)
- Ms. Jennifer J. Rhodes, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 48)
- Dr. Rajiv Patni M.D., Chief Medical Officer (Age 49)
- Mr. Alfred G. Merriweather, Chief Financial Officer (Age 64)
- Mr. Richard A. King, Chief Operating Officer (Age 53)
Has Adamas Pharmaceuticals been receiving favorable news coverage?
News coverage about ADMS stock has trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm rates the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Adamas Pharmaceuticals earned a media sentiment score of 0.06 on Accern's scale. They also assigned press coverage about the specialty pharmaceutical company an impact score of 46.61 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Adamas Pharmaceuticals' major shareholders?
Adamas Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include STATE STREET CORP (10.46%), Point72 Asset Management L.P. (7.55%), BlackRock Inc. (5.50%), BROADFIN CAPITAL, LLC (5.37%), Sphera Funds Management LTD. (1.24%) and JPMorgan Chase & Co. (0.90%). Company insiders that own Adamas Pharmaceuticals stock include Christopher B Prentiss, Great Point Partners Llc, Gregory T Went, Ix Lp Mdv, Jennifer J Rhodes, Rajiv Patni, William J Dawson and William W Ericson. View Institutional Ownership Trends for Adamas Pharmaceuticals.
Which institutional investors are selling Adamas Pharmaceuticals stock?
ADMS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Point72 Asset Management L.P., Citigroup Inc., JPMorgan Chase & Co., Opus Point Partners Management LLC, New York State Common Retirement Fund and Blair William & Co. IL. Company insiders that have sold Adamas Pharmaceuticals company stock in the last year include Christopher B Prentiss, Great Point Partners Llc, Gregory T Went, Jennifer J Rhodes and Rajiv Patni. View Insider Buying and Selling for Adamas Pharmaceuticals.
Which institutional investors are buying Adamas Pharmaceuticals stock?
ADMS stock was bought by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Kornitzer Capital Management Inc. KS, UBS Group AG, BlackRock Inc., Lord Abbett & CO. LLC, Oak Ridge Investments LLC, Deltec Asset Management LLC and SCP Investment LP. Company insiders that have bought Adamas Pharmaceuticals stock in the last two years include Ix Lp Mdv and William W Ericson. View Insider Buying and Selling for Adamas Pharmaceuticals.
How do I buy shares of Adamas Pharmaceuticals?
Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Adamas Pharmaceuticals' stock price today?
One share of ADMS stock can currently be purchased for approximately $29.33.
How big of a company is Adamas Pharmaceuticals?
Adamas Pharmaceuticals has a market capitalization of $802.45 million and generates $570,000.00 in revenue each year. The specialty pharmaceutical company earns $-89,490,000.00 in net income (profit) each year or ($3.97) on an earnings per share basis. Adamas Pharmaceuticals employs 147 workers across the globe.
How can I contact Adamas Pharmaceuticals?
Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 750, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected]
MarketBeat Community Rating for Adamas Pharmaceuticals (ADMS)
MarketBeat's community ratings are surveys of what our community members think about Adamas Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Adamas Pharmaceuticals (NASDAQ:ADMS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
11 Wall Street analysts have issued ratings and price targets for Adamas Pharmaceuticals in the last 12 months. Their average twelve-month price target is $43.00, suggesting that the stock has a possible upside of 46.61%. The high price target for ADMS is $55.00 and the low price target for ADMS is $31.00. There are currently 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $43.00 | $43.00 | $45.6667 | $42.00 |
| Price Target Upside: | 46.61% upside | 53.08% upside | 75.51% upside | 55.56% upside |
Adamas Pharmaceuticals (NASDAQ:ADMS) Consensus Price Target History
Adamas Pharmaceuticals (NASDAQ:ADMS) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
Adamas Pharmaceuticals (NASDAQ:ADMS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Adamas Pharmaceuticals (NASDAQ ADMS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 24.60%
Institutional Ownership Percentage: 93.26%
Adamas Pharmaceuticals (NASDAQ ADMS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/21/2018 | Christopher B Prentiss | CAO | Sell | 567 | $25.98 | $14,730.66 | 17,758 |  |
| 3/21/2018 | Gregory T Went | CEO | Sell | 4,541 | $25.75 | $116,930.75 | 182,610 | |
| 3/21/2018 | Rajiv Patni | Insider | Sell | 1,252 | $25.94 | $32,476.88 | 21,515 | |
| 12/21/2017 | Jennifer J. Rhodes | Insider | Sell | 440 | $32.30 | $14,212.00 | | |
| 6/21/2017 | Great Point Partners Llc | Major Shareholder | Sell | 380,000 | $17.08 | $6,490,400.00 | | |
| 6/21/2017 | Jennifer J. Rhodes | Insider | Sell | 1,041 | $17.53 | $18,248.73 | | |
| 6/19/2017 | Great Point Partners Llc | Major Shareholder | Sell | 350,000 | $17.05 | $5,967,500.00 | | |
| 3/21/2017 | Gregory T Went | CEO | Sell | 2,807 | $17.03 | $47,803.21 | 166,526 | |
| 3/21/2017 | Rajiv Patni | Insider | Sell | 733 | $17.04 | $12,490.32 | 13,642 | |
| 3/21/2017 | William J Dawson | CFO | Sell | 716 | $17.02 | $12,186.32 | 14,284 | |
| 9/16/2016 | Ix Lp Mdv | Major Shareholder | Buy | 62,977 | $16.48 | $1,037,860.96 | | |
| 9/13/2016 | Ix Lp Mdv | Major Shareholder | Buy | 84,376 | $15.58 | $1,314,578.08 | | |
| 9/7/2016 | William W Ericson | Director | Buy | 60,846 | $15.68 | $954,065.28 | | |
| 9/6/2016 | Ix Lp Mdv | Major Shareholder | Buy | 50,919 | $14.79 | $753,092.01 | | |
| 9/6/2016 | William W Ericson | Director | Buy | 7,200 | $15.00 | $108,000.00 | | |
| 9/2/2016 | William W Ericson | Director | Buy | 43,719 | $14.75 | $644,855.25 | | |
| 4/18/2016 | Natalie Mcclure | SVP | Sell | 36,000 | $18.50 | $666,000.00 | 21,006 | |
| 12/7/2015 | Ivan M Lieberburg | Director | Sell | 3,000 | $16.23 | $48,690.00 | 48,000 | |
| 10/5/2015 | Ivan M Lieberburg | Director | Sell | 3,000 | $16.75 | $50,250.00 | 54,000 | |
| 9/8/2015 | Ivan M Lieberburg | Director | Sell | 3,000 | $19.13 | $57,390.00 | 57,000 | |
| 7/6/2015 | Ivan M Lieberburg | Director | Sell | 3,000 | $25.91 | $77,730.00 | | |
| 6/5/2015 | Natalie Mcclure | SVP | Sell | 2,000 | $18.95 | $37,900.00 | | |
| 5/18/2015 | Ix Lp Mdv | Major Shareholder | Sell | 1,643 | $18.04 | $29,639.72 | | |
| 5/15/2015 | Richard H Booth | Director | Sell | 1,000 | $17.85 | $17,850.00 | | |
| 5/14/2015 | Gregory T Went | CEO | Sell | 2,728 | $18.00 | $49,104.00 | | |
| 4/23/2015 | Gregory T Went | CEO | Sell | 3,300 | $18.00 | $59,400.00 | | |
| 4/21/2015 | Gregory T Went | CEO | Sell | 962 | $18.01 | $17,325.62 | | |
| 4/20/2015 | Gregory T Went | CEO | Sell | 2,610 | $18.00 | $46,980.00 | | |
| 4/15/2015 | Richard H Booth | Director | Sell | 1,000 | $17.72 | $17,720.00 | | |
| 4/14/2015 | Gregory T Went | CEO | Sell | 14,757 | $7.15 | $105,512.55 | | |
| 4/10/2015 | William W Ericson | Director | Sell | 37,078 | $18.56 | $688,167.68 | | |
| 4/6/2015 | Ivan M Lieberburg | Director | Sell | 3,000 | $17.44 | $52,320.00 | | |
| 4/6/2015 | Natalie Mcclure | SVP | Sell | 2,000 | $17.44 | $34,880.00 | | |
| 3/19/2015 | Gregory T Went | CEO | Sell | 23,088 | $18.00 | $415,584.00 | | |
| 3/18/2015 | Ix Lp Mdv | Major Shareholder | Sell | 11,723 | $18.02 | $211,248.46 | | |
| 3/16/2015 | Richard H Booth | Director | Sell | 1,000 | $17.36 | $17,360.00 | | |
| 3/13/2015 | Aeris Capital Equity Investmen | Major Shareholder | Sell | 350,000 | $17.23 | $6,030,500.00 | | |
| 2/17/2015 | Richard H Booth | Director | Sell | 1,000 | $16.54 | $16,540.00 | | |
| 2/5/2015 | Natalie Mcclure | SVP | Sell | 2,000 | $16.87 | $33,740.00 | | |
| 2/2/2015 | Ivan M Lieberburg | Director | Sell | 3,000 | $16.77 | $50,310.00 | | |
| 1/5/2015 | Ivan M Lieberburg | Director | Sell | 3,000 | $17.59 | $52,770.00 | | |
| 1/5/2015 | Natalie Mcclure | SVP | Sell | 2,000 | $17.59 | $35,180.00 | | |
| 12/24/2014 | Richard H Booth | Director | Sell | 2,000 | $17.51 | $35,020.00 | | |
| 12/3/2014 | Aeris Capital Equity Investmen | Major Shareholder | Sell | 111,625 | $14.51 | $1,619,678.75 | | |
| 12/1/2014 | Aeris Capital Equity Investmen | Major Shareholder | Sell | 13,615 | $14.54 | $197,962.10 | | |
| 12/1/2014 | Natalie Mcclure | SVP | Sell | 20,000 | $14.50 | $290,000.00 | | |
| 11/26/2014 | Aeris Capital Equity Investmen | Major Shareholder | Sell | 12,500 | $14.77 | $184,625.00 | | |
| 11/25/2014 | Aeris Capital Equity Investmen | Major Shareholder | Sell | 10,000 | $14.85 | $148,500.00 | | |
| 4/15/2014 | William W Ericson | Director | Buy | 300,000 | $16.00 | $4,800,000.00 | | |
(Data available from 1/1/2013 forward)
Adamas Pharmaceuticals (NASDAQ ADMS) News Headlines
| Source: |
|
Adamas Pharmaceuticals (NASDAQ:ADMS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Adamas Pharmaceuticals (NASDAQ:ADMS) Income Statement, Balance Sheet and Cash Flow Statement
Adamas Pharmaceuticals (NASDAQ ADMS) Stock Chart for Thursday, May, 24, 2018
Loading chart…
